硼替佐米原研药与仿制药治疗多发性骨髓瘤的临床观察及药物经济学评价。
Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.
机构信息
Capital Medical University, Beijing 100069, China.
Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.
出版信息
J Healthc Eng. 2022 Mar 29;2022:5201354. doi: 10.1155/2022/5201354. eCollection 2022.
BACKGROUND
Multiple myeloma (MM) is one of the hitherto incurable malignant blood tumors. Bortezomib plays an important role in the treatment of MM.
OBJECTIVE
We aimed to compare effectiveness, safety, and pharmacoeconomic evaluations of the original research drug and the generic drug Bortezomib in the treatment of MM, so as to provide a reasonable basis for the selection of drugs in clinical diagnosis and treatment.
METHODS
A collection of 374 patients with MM were diagnosed and treated with combined Bortezomib in our hospital from July 2019 to January 2020.Two hundred and sixty nine cases met the criteria for inclusion and discharge. According to the different drug manufacturers, divided into the original research drug group ( = 149) and the generic drug group ( = 120). The effectiveness and safety were separately counted, and use the cost-minimization analysis to make the pharmacoeconomic evaluations.
RESULTS
Compared with the results of the two groups, there was no statistical difference between the two groups of treatment efficacy or adverse reaction rates ( > 0.05). The average daily cost of the original research drug group was 2954.38 Chinese yuan (CNY), the average treatment cost per cycle was 32967.69 CNY, the average daily cost of the generic drug group was 2697.29 CNY, and the average treatment cost per cycle was 29129.57 CNY. The price of the generic drug group is lower than the original drug group, and there was a statistical difference between the two groups ( < 0.05).
CONCLUSION
There was no difference between the two groups of effectiveness or safety, and the generic drug is more economical in the treatment.
背景
多发性骨髓瘤（MM）是目前无法治愈的恶性血液病之一。硼替佐米在 MM 的治疗中发挥着重要作用。
目的
比较原研药与仿制药硼替佐米治疗 MM 的有效性、安全性和药物经济学评价，为临床诊治中药物的选择提供合理依据。
方法
收集我院 2019 年 7 月至 2020 年 1 月采用硼替佐米联合方案诊治的 MM 患者 374 例，共 269 例符合纳入和排除标准，根据药物生产厂家不同分为原研药组（ = 149 例）和仿制药组（ = 120 例），分别对两组的有效性和安全性进行计数，并采用成本-最小化分析进行药物经济学评价。
结果
两组患者的治疗效果或不良反应发生率差异均无统计学意义（ > 0.05）。原研药组的日均费用为 2954.38 元，每个治疗周期的治疗费用为 32967.69 元；仿制药组的日均费用为 2697.29 元，每个治疗周期的治疗费用为 29129.57 元。仿制药组的价格低于原研药组，差异有统计学意义（ < 0.05）。
结论
两组患者的疗效或安全性差异均无统计学意义，仿制药在治疗上更经济。
Zotero 插件